Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC decreased its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 40.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,306,220 shares of the company's stock after selling 870,977 shares during the period. Janus Henderson Group PLC owned approximately 1.30% of Day One Biopharmaceuticals worth $16,556,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in DAWN. SG Americas Securities LLC bought a new position in Day One Biopharmaceuticals during the fourth quarter valued at approximately $866,000. MetLife Investment Management LLC raised its holdings in shares of Day One Biopharmaceuticals by 12.4% during the 4th quarter. MetLife Investment Management LLC now owns 34,248 shares of the company's stock worth $434,000 after acquiring an additional 3,781 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in shares of Day One Biopharmaceuticals by 90.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 121,167 shares of the company's stock valued at $1,535,000 after acquiring an additional 57,601 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Day One Biopharmaceuticals by 5.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 535,501 shares of the company's stock valued at $6,785,000 after purchasing an additional 28,053 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Day One Biopharmaceuticals by 43.4% in the fourth quarter. Bank of New York Mellon Corp now owns 244,829 shares of the company's stock valued at $3,102,000 after purchasing an additional 74,091 shares in the last quarter. 87.95% of the stock is owned by institutional investors.

Insider Transactions at Day One Biopharmaceuticals

In other news, General Counsel Adam Dubow sold 4,552 shares of the firm's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $6.26, for a total value of $28,495.52. Following the sale, the general counsel now directly owns 47,136 shares in the company, valued at approximately $295,071.36. This trade represents a 8.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Charles N. York II sold 4,282 shares of the firm's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $26,805.32. Following the completion of the sale, the chief financial officer now owns 265,231 shares of the company's stock, valued at approximately $1,660,346.06. This trade represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 26,725 shares of company stock valued at $167,299. Company insiders own 6.20% of the company's stock.

Day One Biopharmaceuticals Stock Performance

Day One Biopharmaceuticals stock traded down $0.05 during mid-day trading on Wednesday, hitting $6.54. The company's stock had a trading volume of 209,775 shares, compared to its average volume of 1,108,460. The company has a 50 day moving average of $7.36 and a 200-day moving average of $10.68. The stock has a market cap of $662.40 million, a PE ratio of -6.33 and a beta of -1.24. Day One Biopharmaceuticals, Inc. has a one year low of $6.08 and a one year high of $16.76.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.11. The firm had revenue of $30.76 million during the quarter, compared to analysts' expectations of $30.28 million. On average, equities research analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Analysts Set New Price Targets

DAWN has been the topic of a number of recent research reports. Wedbush reaffirmed an "outperform" rating and set a $25.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, May 7th. HC Wainwright restated a "buy" rating and set a $36.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. The Goldman Sachs Group dropped their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a research note on Tuesday, March 25th. Needham & Company LLC reduced their target price on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of "Buy" and a consensus target price of $30.57.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.